je.st
news
Biogen buys UK-based neuropathic pain drug developer for up to $675M
2015-01-12 06:43:14| Biotech - Topix.net
Biogen Idec is getting into the neuropathic pain treatment field with the acquisition of a U.K. drug developer for up to $675 million. The Cambridge biotech firm , known best for its drugs for multiple sclerosis, announced the acquisition of Convergence Pharmaceuticals on the first weekend of the J.P. Morgan Healthcare conference in San Francisco.
Tags: drug
pain
developer
buys
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||